RxDoctor Payments Data

Adam Twickler, APRN

Adult Health · New London, CTNPI 1447847348

Payments from drug & device makers

What this record shows

17 manufacturers reported payments, led by Angiodynamics, Inc. at 57.5% of the total. Reporting peaked in 2023 at $5,056 and has fallen 82.5% since, to $887 in 2025. Among adult health clinicians in CT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$8,004in general payments, 2019–2025

Across 191 payments — averaging $41.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Angiodynamics, Inc.$5K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$683
  • Johnson & Johnson$604
  • Indivior Inc.$421
  • Collegium Pharmaceutical, Inc.$295
  • Azurity Pharmaceuticals, Inc.$275
  • plus $1K from 11 others

What the payments were for

  • Food & beverage$3,50444%
  • Other$4,50056%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,004 in reported general payments places this provider in the 90th percentile of 418 adult health providers in Connecticut.

See all adult health providers in Connecticut

Medicare billing

Part B allowed, 2024
$42,710
Medicare patients
81
Services billed
419

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl321$286,495
RelistorMethylnaltrexone Bromide54$128,232
ZtlidoLidocaine63$65,129
Buprenorphine213$52,333
OxycontinOxycodone Hcl68$31,245
LinzessLinaclotide39$27,113
MovantikNaloxegol Oxalate63$26,096
Xtampza ErOxycodone Myristate35$22,633
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl120$20,806
HorizantGabapentin Enacarbil19$19,854
Oxycodone Hcl754$11,329
SymproicNaldemedine Tosylate16$7,472
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen261$6,309
Hysingla ErHydrocodone Bitartrate18$5,895
Lidocaine49$4,798

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er$295$309,128356 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor$683$128,23254 claims
AbbVieLinzess$55$27,11339 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 418 adult health providers in Connecticut.

Other adult health in New London

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →